Non-interventional study of patients with PN NF1 starting selumetinib in Russia

Trial Identifier: D1340R00002
Sponsor: AstraZeneca
Start Date: March 2023
Primary Completion Date: March 2026
Study Completion Date: March 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia Ekaterinburg, Russia
Russia Kazan, Russia
Russia Novosibirsk, Russia
Russia Saint Petersburg, Russia
Russia, Moskva Moscow, Moskva, Russia, 123112